Talquetamab (Talvey), approved by the FDA in August 2023, is a bispecific antibody that targets both G protein-coupled receptor family C group 5 member D (GPRC5D) – a protein highly expressed on myeloma cells – and CD3, a protein on T cells. This dual targeting helps activate the immune system to recognize and destroy myeloma cells.

Talquetamab is intended for adults with multiple myeloma that has relapsed after receiving at least four prior types of therapy, including a proteasome inhibitor (like bortezomib or carfilzomib), an immunomodulatory agent (like lenalidomide or pomalidomide), and an anti-CD38 monoclonal antibody.

Talquetamab is administered subcutaneously (via injection), typically once a week for the first cycle, followed by bi-weekly infusions thereafter. The first 2-3 doses will be administered in a “step-up dosing schedule” to minimize the number and severity of side effects. The exact duration of treatment depends on individual patient tolerance and response.

In the clinical trial MonumenTAL-1, talquetamab demonstrated a substantial response rate among patients with heavily pretreated relapsed or refractory multiple myeloma. Approximately 73% of patients achieved an overall response, with around 30% experiencing a complete remission.

It's important to note that talquetamab can cause side effects. Some of the most common side effects reported in clinical trials include:

• CRS in up to 73% of patients, but most cases are manageable.
• Skin-related events like rash, dryness, and itching are common, affecting around 60% of patients.
• Dysgeusia (altered taste), which can occur in up to 50% of patients receiving talquetamab.
• Low blood cell counts (including neutropenia) can increase the risk of infections. Neutropenia is reported in about 80% of patients.

For more information on talquetamab, visit talvey.com